Additionally, inhibitors targeting signature genes identified in this study [e.g., the ALOX5AP inhibitor AM679 (41)] could be administered to mouse glioma orthotopic models (e.g., GL261) to assess tumor growth dynamics and immune microenvironment remodeling. The gene discussed is ALOX5AP; the disease is glioma.